Takeshi Hanagiri
Takeshi Hanagiri has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Hidetaka Uramoto
Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan
5 shared publications - Fumihiro Tanaka
Second Department of Surgery University of Occupational and Environmental Health Kitakyushu Japan
4 shared publications Hidehiko Shimokawa
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
2 shared publications- Kenji Ono
RIKEN Center for Computational Science
2 shared publications - Koji Kuroda
Department of Cardiology Hyogo Prefectural Awaji Medical Center Sumoto Japan
2 shared publications Yoshiki Shigematsu
Department of Surgery II, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
2 shared publications
Latest Publications
- Open Access
- 1 December 2020
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 6 (4) , 179-184
Chronic obstructive pulmonary disease severity in middle-aged and older men with osteoporosis associates with decreased bone formation
- 1 December 2020
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 6 (4) , 179-184
Open AccessChronic obstructive pulmonary disease severity in middle-aged and older men with osteoporosis associates with decreased bone formation
- 1 January 2018
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 155 (1) , 382-392.e1
Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung
- 1 January 2018
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 155 (1) , 382-392.e1
Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung
- 3 November 2012
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 18 (6) , 997-1004
Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients
Background Melanoma-associated antigen-A4 (MAGE-A4) is one of the candidates for a target of immunotherapy and is expressed in non-small cell lung cancer (NSCLC). However, tumors sometimes lose human leukocyte antigen (HLA) class I expression, and tumor-specific T cells cannot eliminate the tumor with loss of HLA. However, the relationship between MAGE-A4 expression and HLA loss has remained unclear. Methods Among 363 NSCLC patients who consecutively underwent curative surgery, 187 cases whose material could be analyzed were reviewed. The expression of HLA class I molecules was assessed by immunohistochemical staining. The expression of MAGE-A4 was analyzed by RT-PCR. Results Seventy-seven tumors expressed HLA normally; however, 110 tumors lost HLA. The proportion of patients with a smoking habit and expressing the MAGE-A4 gene in patients with HLA loss was higher than those with HLA expression (p = 0.04 and 0.028, respectively). Five-year overall survival (OS) rate in the patients expressing MAGE-A4 but with loss of HLA was 52.4 %, and OS was significantly poorer than their counterparts (74.0 %, p = 0.036). Multivariate analysis indicated that advanced stage or history of smoking and HLA loss was an independently poor prognostic predictor of OS in NSCLC (p < 0.01 and p = 0.04, respectively). Conclusion HLA class I loss in NSCLC was related to smoking history and MAGE-A4 expression of tumors. HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in NSCLC.
- 3 November 2012
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 18 (6) , 997-1004
Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients
Background Melanoma-associated antigen-A4 (MAGE-A4) is one of the candidates for a target of immunotherapy and is expressed in non-small cell lung cancer (NSCLC). However, tumors sometimes lose human leukocyte antigen (HLA) class I expression, and tumor-specific T cells cannot eliminate the tumor with loss of HLA. However, the relationship between MAGE-A4 expression and HLA loss has remained unclear. Methods Among 363 NSCLC patients who consecutively underwent curative surgery, 187 cases whose material could be analyzed were reviewed. The expression of HLA class I molecules was assessed by immunohistochemical staining. The expression of MAGE-A4 was analyzed by RT-PCR. Results Seventy-seven tumors expressed HLA normally; however, 110 tumors lost HLA. The proportion of patients with a smoking habit and expressing the MAGE-A4 gene in patients with HLA loss was higher than those with HLA expression (p = 0.04 and 0.028, respectively). Five-year overall survival (OS) rate in the patients expressing MAGE-A4 but with loss of HLA was 52.4 %, and OS was significantly poorer than their counterparts (74.0 %, p = 0.036). Multivariate analysis indicated that advanced stage or history of smoking and HLA loss was an independently poor prognostic predictor of OS in NSCLC (p < 0.01 and p = 0.04, respectively). Conclusion HLA class I loss in NSCLC was related to smoking history and MAGE-A4 expression of tumors. HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in NSCLC.
- Open Access
- 1 December 2011
- Published by S. Karger AG in European Surgical Research
- Vol. 47 (4) , 284
SPIGC News
- 1 December 2011
- Published by S. Karger AG in European Surgical Research
- Vol. 47 (4) , 284
Open AccessSPIGC News
- Open Access
- 26 April 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (4) , 585-590
Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung
Not all patients with lung cancer require post-operative adjuvant chemotherapy after a complete resection. However, no useful markers exist for either selecting appropriate candidates or for predicting clinical recurrence. The purpose of the present study was to clarify the clinical role of insulin-like growth factor receptor-1 (IGFR1) in lung adenocarcinoma. Tumor specimens were collected from 182 patients who underwent a complete resection for adenocarcinoma of the lung. The expression of IGFR1 was evaluated by immuno-histochemistry. The genetic status of the epidermal growth factor receptor (EGFR) and K-ras genes was also investigated by PCR-based analyses. Immunohistochemistry and real-time PCR assays were used to evaluate the MET gene association with tyrosine phosphorylation and hepatocyte growth factor (HGF) status, and amplification, respectively. Positive expression of IGFR1 was detected in 43 (23.6%) of the 182 cases. A positive IGFR1 expression was also identified in 12 (42.9%) and 31 (20.1%) of the patients with and without recurrence, respectively (p=0.009). Logistic regression models indicated that positive staining for IGFR1 expression was an independent factor associated with tumor recurrence. IGFR1 expression was associated with a poorer disease-free survival (DFS). Multivariate analysis demonstrated positive IGFR1 expression to be independently associated with an increased risk for poor DFS. The tumors appearing positive for IGFR1 were more frequent among those with K-ras mutations when compared with the wild-type group. IGFR1 expression was associated with reduced DFS correlating with postoperative recurrence. Therefore, the expression status of IGFR1 can be a candidate surrogate marker to select patients who may benefit from adjuvant chemotherapy.
- 26 April 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (4) , 585-590
Open AccessInsulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung
Not all patients with lung cancer require post-operative adjuvant chemotherapy after a complete resection. However, no useful markers exist for either selecting appropriate candidates or for predicting clinical recurrence. The purpose of the present study was to clarify the clinical role of insulin-like growth factor receptor-1 (IGFR1) in lung adenocarcinoma. Tumor specimens were collected from 182 patients who underwent a complete resection for adenocarcinoma of the lung. The expression of IGFR1 was evaluated by immuno-histochemistry. The genetic status of the epidermal growth factor receptor (EGFR) and K-ras genes was also investigated by PCR-based analyses. Immunohistochemistry and real-time PCR assays were used to evaluate the MET gene association with tyrosine phosphorylation and hepatocyte growth factor (HGF) status, and amplification, respectively. Positive expression of IGFR1 was detected in 43 (23.6%) of the 182 cases. A positive IGFR1 expression was also identified in 12 (42.9%) and 31 (20.1%) of the patients with and without recurrence, respectively (p=0.009). Logistic regression models indicated that positive staining for IGFR1 expression was an independent factor associated with tumor recurrence. IGFR1 expression was associated with a poorer disease-free survival (DFS). Multivariate analysis demonstrated positive IGFR1 expression to be independently associated with an increased risk for poor DFS. The tumors appearing positive for IGFR1 were more frequent among those with K-ras mutations when compared with the wild-type group. IGFR1 expression was associated with reduced DFS correlating with postoperative recurrence. Therefore, the expression status of IGFR1 can be a candidate surrogate marker to select patients who may benefit from adjuvant chemotherapy.
- Open Access
- 1 January 2011
- Published by The University of Occupational and Environmental Health, Japan in Journal of UOEH
- Vol. 33 (2) , 157-161
Management of Patients with Bronchial Foreign Bodies
The aspiration of foreign bodies into the bronchus frequently occurs in children as well as in elderly people. Foreign bodies in the airway not only cause chronic cough and pneumonia, but also result in life-threatening conditions, such as dyspnea and cyanosis. This report presents the clinical characteristics of 6 patients with bronchial foreign bodies who were treated between 2006 and 2010, including 4 male and 2 female patients. The age of the patients ranged from 8 to 83 years old. Foreign bodies were located in the right bronchial tree in all the patients. Chest X-rays showed pneumonia or atelectasis in 5 out of 6 patients. The foreign bodies were an artificial teeth or a tooth in 5 patients, and a fish bone in 1 patient. Five patients had fiberoptic bronchoscopy under local anesthesia, although an 8-year-old girl required general anesthesia with a laryngeal mask. Surgery was needed in only one case. Bronchial foreign bodies present a large range of symptoms, from trivial symptoms to irreversible damage to the bronchus and the lung, which can be life threatening. Nonspecific respiratory symptoms may be mistakenly attributed to other medical diagnoses unless there is a clear history of aspiration. However, an early diagnosis is very important, because inflammatory granulation due to long-term impaction of foreign bodies makes its removal difficult.
- 1 January 2011
- Published by The University of Occupational and Environmental Health, Japan in Journal of UOEH
- Vol. 33 (2) , 157-161
Open AccessManagement of Patients with Bronchial Foreign Bodies
The aspiration of foreign bodies into the bronchus frequently occurs in children as well as in elderly people. Foreign bodies in the airway not only cause chronic cough and pneumonia, but also result in life-threatening conditions, such as dyspnea and cyanosis. This report presents the clinical characteristics of 6 patients with bronchial foreign bodies who were treated between 2006 and 2010, including 4 male and 2 female patients. The age of the patients ranged from 8 to 83 years old. Foreign bodies were located in the right bronchial tree in all the patients. Chest X-rays showed pneumonia or atelectasis in 5 out of 6 patients. The foreign bodies were an artificial teeth or a tooth in 5 patients, and a fish bone in 1 patient. Five patients had fiberoptic bronchoscopy under local anesthesia, although an 8-year-old girl required general anesthesia with a laryngeal mask. Surgery was needed in only one case. Bronchial foreign bodies present a large range of symptoms, from trivial symptoms to irreversible damage to the bronchus and the lung, which can be life threatening. Nonspecific respiratory symptoms may be mistakenly attributed to other medical diagnoses unless there is a clear history of aspiration. However, an early diagnosis is very important, because inflammatory granulation due to long-term impaction of foreign bodies makes its removal difficult.
- Open Access
- 1 January 2006
- Published by Japan Lung Cancer Society in Haigan
- Vol. 46 (2) , 127-131
Clinical Usefulness of FDG-PET in the Diagnosis of Lung Cancer
- 1 January 2006
- Published by Japan Lung Cancer Society in Haigan
- Vol. 46 (2) , 127-131
Open AccessClinical Usefulness of FDG-PET in the Diagnosis of Lung Cancer